<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04931615</url>
  </required_header>
  <id_info>
    <org_study_id>287482</org_study_id>
    <secondary_id>2021-002624-20</secondary_id>
    <nct_id>NCT04931615</nct_id>
  </id_info>
  <brief_title>ARTISS a Single-centre Randomised Control Study</brief_title>
  <acronym>ARTISS</acronym>
  <official_title>The Influence of ARTISS on Post-operative Abdominal Drainage and Seroma Formation in DIEP/MS-TRAM Free Flap Breast Reconstruction Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mid and South Essex NHS Foundation Trust</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mid and South Essex NHS Foundation Trust</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Influence of ARTISS on post-operative abdominal drainage and seroma formation in&#xD;
      DIEP/MS-TRAM free flap breast reconstruction patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The principle aim of the study is to investigate the effect of ARTISS on abdominal wound&#xD;
      drainage whether this could result in earlier drain removal and earlier patient discharge&#xD;
      from hospital. The primary outcome investigated will be post- operative abdominal drainage&#xD;
      duration in days which is vital information during this Covid pandemic to reduce hospital&#xD;
      stay (and therefore possible Covid exposure) which could result in earlier discharge from&#xD;
      hospital, as well as significantly reducing cost of the procedure to the NHS and frees&#xD;
      in-patient beds for more efficient use of resources.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">January 1, 2022</start_date>
  <completion_date type="Anticipated">August 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">August 1, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>Randomised controlled trial</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
    <masking_description>Blinded patient and blinded assessor</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>post-operative abdominal mean drainage duration</measure>
    <time_frame>7 days</time_frame>
    <description>post-operative abdominal mean drainage duration</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">134</enrollment>
  <condition>Breast Neoplasms</condition>
  <condition>Mammaplasty</condition>
  <arm_group>
    <arm_group_label>without ARTISS</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Surgery performed without active comparative</description>
  </arm_group>
  <arm_group>
    <arm_group_label>with ARTISS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Surgery performed with active comparative</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ARTISS 4mL Fibrin Sealant Topical Solution (Frozen)</intervention_name>
    <description>Wound seallant</description>
    <arm_group_label>with ARTISS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>no ARTISS</intervention_name>
    <description>Wound closed without seallant</description>
    <arm_group_label>without ARTISS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Female adult (age 18-80)&#xD;
&#xD;
          -  Patients planned for immediate or delayed DIEP/MS-TRAM breast reconstruction&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients who are unable to consent or do not consent&#xD;
&#xD;
          -  Clotting disorder&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Individuals whose immune system is depressed or who have some types of anaemia (e.g.&#xD;
             sickle cell disease or haemolytic anaemia).&#xD;
&#xD;
          -  COVID positive&#xD;
&#xD;
          -  Known previous allergic reactions to ARTISS&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mary Morgan, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Mid and South Essex NHS Foundation Trust</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Isuruperera Manimeldura, MD</last_name>
    <phone>01245556717</phone>
    <email>manimelduraisuruperera@nhs.net</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Carol Alves, MRes</last_name>
    <phone>01268394672</phone>
    <email>carol.alves@nhs.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Mid and South Essex NHS Foundation Trust</name>
      <address>
        <city>Broomfield</city>
        <state>Essex</state>
        <zip>CM1 7ET</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
    <contact>
      <last_name>Mary Morgan, MD</last_name>
      <phone>01245556717</phone>
      <email>mary.morgan10@nhs.net</email>
    </contact>
    <contact_backup>
      <last_name>Isuruperera Manimeldura, MD</last_name>
      <phone>01245556717</phone>
      <email>manimelduraisuruperera@nhs.net</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>June 11, 2021</study_first_submitted>
  <study_first_submitted_qc>June 16, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 18, 2021</study_first_posted>
  <last_update_submitted>August 31, 2021</last_update_submitted>
  <last_update_submitted_qc>August 31, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>muscle-sparing transverse rectus abdominis myocutaneous flap</keyword>
  <keyword>Deep Inferior Epigastric Artery Perforator</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fibrin Tissue Adhesive</mesh_term>
    <mesh_term>Thrombin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

